398 related articles for article (PubMed ID: 23583245)
1. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies.
Dake MD; Ansel GM; Jaff MR; Ohki T; Saxon RR; Smouse HB; Snyder SA; O'Leary EE; Tepe G; Scheinert D; Zeller T;
J Am Coll Cardiol; 2013 Jun; 61(24):2417-2427. PubMed ID: 23583245
[TBL] [Abstract][Full Text] [Related]
2. Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Dake MD; Ansel GM; Jaff MR; Ohki T; Saxon RR; Smouse HB; Machan LS; Snyder SA; O'Leary EE; Ragheb AO; Zeller T;
Circulation; 2016 Apr; 133(15):1472-83; discussion 1483. PubMed ID: 26969758
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results.
Dake MD; Ansel GM; Jaff MR; Ohki T; Saxon RR; Smouse HB; Zeller T; Roubin GS; Burket MW; Khatib Y; Snyder SA; Ragheb AO; White JK; Machan LS;
Circ Cardiovasc Interv; 2011 Oct; 4(5):495-504. PubMed ID: 21953370
[TBL] [Abstract][Full Text] [Related]
4. Two-year analysis of the Japanese cohort from the Zilver PTX randomized controlled trial supports the validity of multinational clinical trials.
Ohki T; Yokoi H; Kichikawa K; Kimura T; Snyder SA; Ragheb AO; O'Leary EE; Jaff MR; Ansel GM; Dake MD
J Endovasc Ther; 2014 Oct; 21(5):644-53. PubMed ID: 25290792
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel-Coated Zilver PTX Drug-Eluting Stent Treatment Does Not Result in Increased Long-Term All-Cause Mortality Compared to Uncoated Devices.
Dake MD; Ansel GM; Bosiers M; Holden A; Iida O; Jaff MR; Lottes AE; O'Leary EE; Saunders AT; Schermerhorn M; Yokoi H; Zeller T
Cardiovasc Intervent Radiol; 2020 Jan; 43(1):8-19. PubMed ID: 31502026
[TBL] [Abstract][Full Text] [Related]
6. Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 12-Month Results.
Yokoi H; Ohki T; Kichikawa K; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Snyder SA; Dake MD
JACC Cardiovasc Interv; 2016 Feb; 9(3):271-277. PubMed ID: 26847118
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized Trial.
Gouëffic Y; Torsello G; Zeller T; Esposito G; Vermassen F; Hausegger KA; Tepe G; Thieme M; Gschwandtner M; Kahlberg A; Schindewolf M; Sapoval M; Diaz-Cartelle J; Stavroulakis K;
Circulation; 2022 Nov; 146(21):1564-1576. PubMed ID: 36254728
[TBL] [Abstract][Full Text] [Related]
8. Does endovascular treatment of infra-inguinal arterial disease with drug-eluting stents offer better results than angioplasty with or without bare metal stents?
Antoniou GA; Georgakarakos EI; Antoniou SA; Georgiadis GS
Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):282-5. PubMed ID: 24729201
[TBL] [Abstract][Full Text] [Related]
9. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study.
Dake MD; Scheinert D; Tepe G; Tessarek J; Fanelli F; Bosiers M; Ruhlmann C; Kavteladze Z; Lottes AE; Ragheb AO; Zeller T;
J Endovasc Ther; 2011 Oct; 18(5):613-23. PubMed ID: 21992630
[TBL] [Abstract][Full Text] [Related]
10. A Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal Lesions: The BATTLE Trial.
Gouëffic Y; Sauguet A; Desgranges P; Feugier P; Rosset E; Ducasse E; Kaladji A; Salomon du Mont L; Pernès JM; Commeau P; Lermusiaux P; Leclere B; Guyomarc'h B; Hoffmann CT; Maurel B
JACC Cardiovasc Interv; 2020 Feb; 13(4):447-457. PubMed ID: 32081238
[TBL] [Abstract][Full Text] [Related]
11. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial.
Gray WA; Keirse K; Soga Y; Benko A; Babaev A; Yokoi Y; Schroeder H; Prem JT; Holden A; Popma J; Jaff MR; Diaz-Cartelle J; Müller-Hülsbeck S;
Lancet; 2018 Oct; 392(10157):1541-1551. PubMed ID: 30262332
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness Study of Drug-Eluting and Bare-Metal Peripheral Artery Stents in Endovascular Femoropopliteal Artery Revascularization.
Jeon-Slaughter H; Khalili H; Tsai S; Armstrong EJ; Shammas NW; Jawaid O; Lu H; Addo T; Gigliotti O; Abu-Fadel M; Banerjee S
J Invasive Cardiol; 2018 Oct; 30(10):373-379. PubMed ID: 30279293
[TBL] [Abstract][Full Text] [Related]
13. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents.
Zeller T; Dake MD; Tepe G; Brechtel K; Noory E; Beschorner U; Kultgen PL; Rastan A
JACC Cardiovasc Interv; 2013 Mar; 6(3):274-81. PubMed ID: 23517839
[TBL] [Abstract][Full Text] [Related]
14. Impact of Chronic Renal Failure on Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Artery Disease: Subgroup Analysis from Zilver PTX Post-Market Surveillance Study in Japan.
Ogawa Y; Yokoi H; Ohki T; Kichikawa K; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Saunders AT; Dake MD
Cardiovasc Intervent Radiol; 2017 Nov; 40(11):1669-1677. PubMed ID: 28488101
[TBL] [Abstract][Full Text] [Related]
15. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease).
Lammer J; Zeller T; Hausegger KA; Schaefer PJ; Gschwendtner M; Mueller-Huelsbeck S; Rand T; Funovics M; Wolf F; Rastan A; Gschwandtner M; Puchner S; Ristl R; Schoder M
J Am Coll Cardiol; 2013 Oct; 62(15):1320-7. PubMed ID: 23831445
[TBL] [Abstract][Full Text] [Related]
16. Prediction Model for Freedom from TLR from a Multi-study Analysis of Long-Term Results with the Zilver PTX Drug-Eluting Peripheral Stent.
Dake MD; Fanelli F; Lottes AE; O'Leary EE; Reichert H; Jiang X; Fu W; Iida O; Zen K; Schermerhorn M; Zeller T; Ansel GM
Cardiovasc Intervent Radiol; 2021 Feb; 44(2):196-206. PubMed ID: 33025243
[TBL] [Abstract][Full Text] [Related]
17. Drug-Eluting Stent vs Percutaneous Transluminal Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis: Results From a Retrospective 1-Year Multicenter Study.
Murata N; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Yokoi H; Tosaka A; Tanaka N; Iida O
J Endovasc Ther; 2016 Aug; 23(4):642-7. PubMed ID: 27099284
[TBL] [Abstract][Full Text] [Related]
18. Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results.
Kichikawa K; Ichihashi S; Yokoi H; Ohki T; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Snyder SA; Dake MD
Cardiovasc Intervent Radiol; 2019 Mar; 42(3):358-364. PubMed ID: 30411151
[TBL] [Abstract][Full Text] [Related]
19. Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With Femoropopliteal Arterial Disease.
Bausback Y; Wittig T; Schmidt A; Zeller T; Bosiers M; Peeters P; Brucks S; Lottes AE; Scheinert D; Steiner S
J Am Coll Cardiol; 2019 Feb; 73(6):667-679. PubMed ID: 30765033
[TBL] [Abstract][Full Text] [Related]
20. Randomized clinical Trial Comparing drug Eluting Stent Zilver PTX® Versus Bare Metal Stent Zilver Flex® for Treatment of Lesions in Femoral and Popliteal Arteries in Chronic Limb Threatening Ischemia.
Fransson T; Gottsäter A; Abdulrasak M; Malina M; Resch T
Vasc Endovascular Surg; 2023 Oct; 57(7):706-716. PubMed ID: 37085152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
